HEOR

News

NICE backs wider NHS use of multiple myeloma drug Nexpovio

More than 1,000 people with incurable blood cancer multiple myeloma could be eligible for treatment with Menarini Stemline UK’s Nexpovio after NICE backed NHS use of the d

News

NICE backs AbbVie’s oral therapy for migraine prevention

AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and W

News

Pfizer’s Velsipity heading for NHS use in ulcerative colitis

Up to 25,000 people with ulcerative colitis (UC) in England could be in line for treatment with Pfizer’s once-daily oral therapy Velsipity, after NICE recommended its use

News

Steve Davis, president and chief executive of Acadia Pharma

Acadia pulls trials of pimavanserin after schizophrenia fail

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.

News

UK access disparity resolved as NICE backs RCC therapy

Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and Bristol-Myers Squibb’s Opdivo will now be ab

News

Surprise Enhertu rejection follows NICE process change

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described

NICE backs wider NHS use of multiple myeloma drug Nexpovio

NICE backs AbbVie’s oral therapy for migraine prevention

Pfizer’s Velsipity heading for NHS use in ulcerative colitis

Acadia pulls trials of pimavanserin after schizophrenia fail

UK access disparity resolved as NICE backs RCC therapy

Surprise Enhertu rejection follows NICE process change

J&J claims FDA's latest national priority voucher

The AI imperative: Establishing the standard for modern clin...

HEOR

Editor's Picks